Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cha Vaccine Research Institute Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions. These actions are distributed across 2 distinct examiners, which means that each pending matter is being reviewed by a different individual. This distribution prevents a concentration of workload under any single examiner and allows for diverse perspectives on the company's applications.
The prosecution activity is spread across 2 distinct art units. This indicates that the company's filings cover multiple technical sub-specialties within the Biotechnology & Pharmaceuticals sector, each subject to different departmental standards. Ekaterina Poliakova-Georgan is the busiest examiner for the portfolio, with 1 pending office action. Because the number of pending actions matches the number of examiners, no single individual is currently managing a concentration of the company's workload. Navigating 2 distinct art units and 2 examiners requires the company to adapt to various specialized technical requirements simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 63.9% | +18.1% |
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563350 | IMMUNO-ONCOLOGY THERAPEUTIC COMPOSITION USING ADJUVANT INCLUDING LIPOPEPTIDES AND POLY (I:C) | POLIAKOVA-GEORGAN, EKATERINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037022 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT | ALLEN, MICHAEL D | 48d |
| 18563350 | IMMUNO-ONCOLOGY THERAPEUTIC COMPOSITION USING ADJUVANT INCLUDING LIPOPEPTIDES AND POLY (I:C) | POLIAKOVA-GEORGAN, EKATERINA | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18563350 | IMMUNO-ONCOLOGY THERAPEUTIC COMPOSITION USING ADJUVANT INCLUDING LIPOPEPTIDES AND POLY (I:C) | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103§112Other | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18037022 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT | ALLEN, MICHAEL D | 1671 | §103 | Final Rejection | 48d | Pending | May 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCha Vaccine Research Institute Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Ekaterina Poliakova-Georgan has the most, with 1 of Cha Vaccine Research Institute Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
